Cargando…

COVID-19 in persons with multiple sclerosis treated with ocrelizumab – A pharmacovigilance case series

Detalles Bibliográficos
Autores principales:	Hughes, Richard, Pedotti, Rosetta, Koendgen, Harold
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228884/ https://www.ncbi.nlm.nih.gov/pubmed/32570202 http://dx.doi.org/10.1016/j.msard.2020.102192

Ejemplares similares

COVID-19 in ocrelizumab-treated people with multiple sclerosis
por: Hughes, Richard, et al.
Publicado: (2021)

Understanding the impacts of COVID-19 pandemic in people with multiple sclerosis treated with ocrelizumab
por: Pedotti, Rosetta, et al.
Publicado: (2021)

Clinical outcomes of COVID-19 in patients with multiple sclerosis treated with ocrelizumab in the pre- and post-SARS-CoV-2 vaccination periods: Insights from Israel
por: Weberpals, Janick, et al.
Publicado: (2022)

COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab
por: Buttari, Fabio, et al.
Publicado: (2021)

Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab
por: Suwanwongse, Kulachanya, et al.
Publicado: (2020)

Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis
por: Hauser, Stephen L., et al.
Publicado: (2021)

Cas d’infection à la COVID-19 chez des personnes atteintes de sclérose en plaques (SEP) traitées par ocrelizumab (OCR) : actualisation des données de pharmacovigilance
por: Hughes, Richard, et al.
Publicado: (2021)

Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis
por: Barkhof, Frederik, et al.
Publicado: (2019)

Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis
por: Hauser, Stephen L., et al.
Publicado: (2023)

Case Report: Covid-19 in Multiple Sclerosis Patients Treated With Ocrelizumab: A Case Series
por: De Mercanti, Stefania F., et al.
Publicado: (2021)

Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab
por: Habek, Mario, et al.
Publicado: (2022)

Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension
por: Hauser, Stephen L., et al.
Publicado: (2020)

Ocrelizumab: A Review in Multiple Sclerosis
por: Lamb, Yvette N.
Publicado: (2022)

COVID-19 in Argentine teriflunomide-treated multiple sclerosis patients: First national case series.
por: Luetic, Geraldine, et al.
Publicado: (2021)

Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab
por: Iannetta, Marco, et al.
Publicado: (2020)

Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic
por: van Lierop, Zoë YGJ, et al.
Publicado: (2021)

COVID-19 Vaccine Failure in a Patient with Multiple Sclerosis on Ocrelizumab
por: Chilimuri, Sridhar, et al.
Publicado: (2021)

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19
por: Rolfes, Leoni, et al.
Publicado: (2021)

Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab
por: Thornton, Jeanine Rempe, et al.
Publicado: (2020)

Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis
por: Cellerino, Maria, et al.
Publicado: (2021)

Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials
por: Giovannoni, Gavin, et al.
Publicado: (2021)

Mast Cells in the Pathogenesis of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
por: Costanza, Massimo, et al.
Publicado: (2012)

Ocrelizumab: a new milestone in multiple sclerosis therapy
por: Mulero, Patricia, et al.
Publicado: (2018)

Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
por: Turner, Benjamin, et al.
Publicado: (2019)

Ocrelizumab for the Treatment of Multiple Sclerosis: Safety, Efficacy, and Pharmacology
por: Mancinelli, Chiara Rosa, et al.
Publicado: (2021)

Pregnancy outcome following exposure to ocrelizumab in multiple sclerosis
por: Chey, Shin Yee, et al.
Publicado: (2022)

Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients
por: Akgün, Katja, et al.
Publicado: (2022)

Treating primary-progressive multiple sclerosis: potential of ocrelizumab and review of B-cell therapies
por: Feng, Jenny J, et al.
Publicado: (2017)

Acute cerebellitis requiring posterior fossa decompression after COVID-19 vaccination in an ocrelizumab-treated patient with multiple sclerosis
por: Brecl Jakob, Gregor, et al.
Publicado: (2022)

Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS
por: Arnold, Douglas L, et al.
Publicado: (2022)

Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β
por: Simpson-Yap, Steve, et al.
Publicado: (2022)

New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab
por: Frau, Jessica, et al.
Publicado: (2018)

Ocrelizumab Depletes CD20(+) T Cells in Multiple Sclerosis Patients
por: Gingele, Stefan, et al.
Publicado: (2018)

Real-world experience of ocrelizumab in multiple sclerosis in an Arab population
por: Garcia-Cañibano, Beatriz, et al.
Publicado: (2021)

Safety and patient experience with at‐home infusion of ocrelizumab for multiple sclerosis
por: Barrera, Britney, et al.
Publicado: (2023)

Viral pericarditis following ocrelizumab in a multiple sclerosis patient
por: Miele, Giuseppina, et al.
Publicado: (2023)

Breast Carcinoma After Ocrelizumab Therapy in Multiple Sclerosis Patients: A Case Series and Literature Review
por: Kelsey, Andrew, et al.
Publicado: (2021)

Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort Study
por: Seery, Nabil, et al.
Publicado: (2021)

Myelin water imaging in relapsing multiple sclerosis treated with ocrelizumab and interferon beta-1a
por: Kolind, Shannon, et al.
Publicado: (2022)

The big challenge for neurologists in treating patients with multiple sclerosis in the post-COVID-19 era
por: Naser Moghadasi, Abdorreza
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tpbgv70lk1bt8p2153gfgfnb3n